In contrast to the classical chemotherapeutic agents, the targeted drugs did not prove very effective in our experiments, although the tyrosine kinase inhibitors bosutinib (Src kinase), dasatinib (BCR/ABL, Src kinase) and sorafenib (VEGFR, PDGFR, Raf kinase) showed efficacy in some of our glioma cultures. The gene discussed is BCR; the disease is central nervous system cancer.